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Abstract
Background: Haematopoietic stem cells (HSCs) first arise during development in the
aorta-gonad-mesonephros (AGM) region of the embryo from a population of
haemogenic endothelial cells which undergo endothelial-to-haematopoietic
transition (EHT). Despite the progress achieved in recent years, the molecular
mechanisms driving EHT are still poorly understood, especially in human where the
AGM region is not easily accessible.
Results: In this study, we take advantage of a human pluripotent stem cell (hPSC)
differentiation system and single-cell transcriptomics to recapitulate EHT in vitro and
uncover mechanisms by which the haemogenic endothelium generates early
haematopoietic cells. We show that most of the endothelial cells reside in a
quiescent state and progress to the haematopoietic fate within a defined time
window, within which they need to re-enter into the cell cycle. If cell cycle is
blocked, haemogenic endothelial cells lose their EHT potential and adopt a non-
haemogenic identity. Furthermore, we demonstrate that CDK4/6 and CDK1 play a
key role not only in the transition but also in allowing haematopoietic progenitors to
establish their full differentiation potential.
Conclusion: We propose a direct link between the molecular machineries that
control cell cycle progression and EHT.
Background
The first self-renewing haematopoietic stem cells (HSCs) are generated from the hae-
mogenic endothelium, a specialised population of endothelial cells, located in the
aorta-gonad-mesonephros (AGM) region [1–3]. This process is known as endothelial-
to-haematopoietic transition (EHT) and is characterised by the appearance of intra-
aortic haematopoietic clusters (IAHCs). IAHCs are physically associated with the hae-
mogenic endothelium which is lining the ventral wall of the dorsal aorta in human [4,
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5]. One of the first events that precedes EHT is the expression of RUNX1 in a subset
of endothelial cells. Thus, RUNX1 expression marks the haemogenic endothelium
where IAHCs will subsequently emerge [6]. It has been shown that RUNX1 activates
the haematopoietic programme and at the same time mediates the upregulation of
transcription factors (e.g. GFI1 and GFI1B) which in turn repress endothelial genes [7].
This dual role of RUNX1 possibly depends on its crosstalk with other key regulators of
haematopoiesis such as TAL1 and GATA2 [8, 9]. In addition to the AGM, other sec-
ondary sites have been reported to produce HSCs from haemogenic endothelial cells
through EHT later on during development, such as placenta, vitelline/umbilical arteries,
and embryonic head [5, 10–14]. These first HSCs migrate to the foetal liver where their
number dramatically increases, both as a consequence of proliferation and due to the
contribution of secondary haematopoietic sites [5, 14]. Despite its importance, the
mechanisms controlling EHT remain to be fully uncovered, especially in human where
these developmental stages are difficult to access for obvious ethical reasons. To bypass
these limitations, several groups have developed in vitro methods that recapitulate pro-
duction of haematopoietic cells through the generation of an intermediate endothelial
state [15–21].
Here, we took advantage of human pluripotent stem cells (hPSCs) to model haemato-
poietic development in vitro and used single-cell transcriptomics to dissect this process.
We show that distinct populations are generated during EHT, including a population
of haematopoietic progenitor cells that have multilineage differentiation potential. Fur-
thermore, we demonstrated a tight link between cell cycle progression and EHT. In-
deed, endothelial cells are quiescent and re-enter cell cycle to differentiate into
haematopoietic progenitor cells. Inhibition of the cell cycle blocks EHT and causes
endothelial cells to lose haemogenic potential. Finally, we demonstrated that cell cycle
regulators such as CDK4/6 and CDK1 are not only essential for EHT but also control
the capacity of nascent haematopoietic progenitors to differentiate. Together, our re-
sults uncover new mechanisms controlling the production of definitive haematopoietic
cells which will be essential not only to understand blood cell development but also to
improve protocols for generating these cells in vitro.
Results
hPSC differentiation provides an in vitro model of endothelial-to-haematopoietic
transition
In order to gain insight into mechanisms driving human definitive haematopoiesis, we
utilised a system for the differentiation of hPSCs (Fig. 1a) [22, 23]. This in vitro system
recapitulates a natural path of development that leads to the production of an inter-
mediate population of endothelial cells with haemogenic potential. Between EHT day 3
(D3) and EHT day 5 (D5), these endothelial cells generate round clusters that progres-
sively increase in size and release single haematopoietic cells in the culture medium
(Fig. 1b). Importantly, these haematopoietic cells can further differentiate into myeloid
cells, foetal γ-globin-producing erythroid cells (Fig. 1c, Additional file 1: Fig. S1a, b),
and T lymphocytes [23–25]. Transcriptionally, the process is marked by the gradual
downregulation of endothelial markers (e.g. CDH5, VWF) and concomitant upregula-
tion of blood markers (e.g. SPI1, KLF1), with key haematopoietic stem/progenitor cell
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(HSPC) genes peaking at EHT D3 (e.g. RUNX1, MYB, and GATA2) (Additional file 1:
Fig. S1c, Fig. 1d, e). Taken together, our data show that differentiation of hPSCs mor-
phologically resembles the generation of IAHCs [1, 2, 5, 25] and that the production of
haematopoietic progenitors in vitro culminates around 3–5 days of EHT culture (Add-
itional file 1: Fig. S1c). For the aforementioned reasons, we selected this interval for our
subsequent analyses.
Single-cell analysis revealed four distinct populations during in vitro EHT
EHT is a dynamic process with different cell types and states coexisting, thereby ren-
dering bulk analyses difficult to interpret. To overcome this limitation and resolve the
Fig. 1 Culture system for modelling EHT in vitro. a Schematic of the differentiation protocol used to model
EHT with hPSCs. D, day. b Representative images of cells progressing through EHT. Scale bar is 400 μm. c
Quantification of colonies generated in a CFU assay using cells collected at EHT D5. Data represent
means ± SEM of 3 independent experiments. BFU-E, burst forming unit-erythroid; CFU-E, colony forming
unit-erythroid; CFU-GM, colony forming unit-granulocyte-macrophage; CFU-G, colony forming unit-
granulocyte; CFU-M, colony forming unit-macrophage; CFU-GEMM, colony forming unit-granulocyte-
erythrocyte-macrophage-megakaryocyte. d, e Flow cytometry analysis of d cells at D8/EHT D0 and e during
EHT culture at multiple time points. Results are representative of at least 3 independent experiments
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inherent heterogeneity of cell types generated during in vitro differentiation, we took
advantage of single-cell RNA sequencing (scRNA-seq). In brief, cells were collected at
EHT D3 and D5, processed using the Chromium 10X Genomics system, and analysed
following the Seurat workflow [26]. Following quality control, 3877 cells from EHT D3
and 2152 from EHT D5 were used in downstream analyses. In both datasets, we identi-
fied four distinct populations (Fig. 2a, b) that were annotated based on marker genes
and the presence of known lineage-specific signature genes (Fig. 2c, Additional file 1:
Fig. S2a). Specifically, we identified a population of endothelial cells, positive for CDH5
and PECAM1; mesenchymal cells, positive for CDH2, KRT8, and TAGLN; and two
clusters of haematopoietic cells: haematopoietic progenitor cells (HPCs) and erythroid
cells. Cells in the HPC cluster displayed expression of stem cell genes such as RUNX1
and GATA2, as well as low expression of early erythroid and myeloid genes, e.g.
GATA1 and CD33. Cells in the erythroid cluster expressed erythroid lineage genes, e.g.
KLF1, ALAS2, and GYPA (Fig. 2c, Additional file 1: Fig. S2a) and had immature cell
Fig. 2 scRNA-seq reveals distinct cell types generated during hPSC differentiation. a Heatmap of the marker
genes for each cluster. For this analysis, data from EHT D3 and EHT D5 were merged. b tSNE plots showing
comparison of samples collected at EHT D3 and EHT D5. Four populations were identified based on
transcriptional identity. Pie charts are showing the percentage and absolute number (in brackets) of cells in
each cluster. Transcriptional data was used to order cells along differentiation trajectories, from endothelial
cells (right) to the haematopoietic and mesenchymal branches (left). c tSNE plots of merged data from EHT
D3 and EHT D5. Expression of relevant lineage markers is shown
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morphology as shown by cytospin staining (Additional file 1: Fig. S2b) [27]. This cluster
was therefore annotated as early erythroid progenitors.
To reconstruct the differentiation trajectory of haematopoietic cells during EHT, we
compared cells from EHT D3 and EHT D5 (Fig. 2b). Our analyses revealed a marked
reduction of endothelial cells and an increase of erythroid progenitors. Conversely,
HPCs and mesenchymal cells only showed a minor increase. Pseudotime differentiation
trajectories suggested that the haematopoietic and mesenchymal compartments both
derived from a common endothelial population. Along this differentiation trajectory,
endothelial cells gradually downregulated endothelial specific genes and concomitantly
upregulated either mesenchymal or haematopoietic markers (Additional file 1: Fig.
S3a). To validate the pseudotime differentiation trajectory, we sequenced further 1764
CD34+/CD43− cells sorted at EHT D0 (Additional file 1: Fig. S3b). Our analysis dem-
onstrated that most cells at EHT D0 were endothelial, as shown by the positive expres-
sion of multiple endothelial marker genes (e.g. CDH5, PECAM1, KDR, THY1).
Importantly, we did not observe expression of haematopoietic lineage associated genes,
demonstrating that haematopoietic cells are subsequently generated. Accordingly, cells
collected at EHT D0 were not able to generate blood colonies in a CFU assay. In
addition, none of the identified clusters had a clear mesenchymal transcriptional signa-
ture. However, a small population co-expressed endothelial (e.g. KDR, THY1) and mes-
enchymal markers (e.g. COL1A1, CDH2, CDH11, KRT8) at low level, suggesting that a
fraction of cells displayed a mixed endothelial/mesenchymal identity at EHT D0 and
represented an early stage of mesenchymal commitment.
Identification and functional validation of multipotent HPCs
Based on our scRNA-seq data, we devised a sorting strategy to isolate each of the popu-
lations identified above. We predicted that combinations of three cell surface markers
(CDH5, CD43, and CD44) (Fig. 2c) were sufficient to allow sorting of the four popula-
tions. CDH5 was mainly expressed in the endothelial cluster and to a lower extent in
HPCs. The pan-haematopoietic CD43 was expressed in HPCs and erythroid progeni-
tors (Fig. 2c, Additional file 1: Fig. S2a). Both these genes are known to mark emerging
HSPCs in the human dorsal aorta during development [28]. Finally, CD44 appeared to
be prevalently expressed in mesenchymal cells and HPCs (Fig. 2c). CD44 was previ-
ously shown to be expressed on IAHCs emerging during EHT in both human and
mouse [29–31].
Immunostaining analyses confirmed that CDH5, CD43, and CD44 were co-expressed
on the clusters of cells produced at EHT D5 (Fig. 3a). In addition, these cells expressed
the master regulator of definitive haematopoiesis RUNX1 and were therefore likely to
correspond to the HPC cluster identified in our single-cell analysis (Additional file 1:
Fig. S4a). A lower expression of RUNX1 was also visible in some of the surrounding
endothelial cells, possibly marking haemogenic endothelial cells in transition to the
haematopoietic fate, consistent with what previously described in vivo [6].
Next, using combinations of the three cell surface markers, we isolated six distinct
populations (Fig. 3b) which were assessed for their capacity to generate blood cells in a
CFU assay (Fig. 3c). Cells in P1 (CDH5−/CD44+/CD43−) and P4 (CDH5+/CD44+/
CD43−), predicted to label mesenchymal and endothelial populations, respectively, did
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not show haematopoietic potential in CFU assay. To further confirm their mesenchy-
mal and endothelial identity, cells from P1 and P4 gates were re-plated and further cul-
tured (Additional file 1: Fig. S4b-g). After 10 days in culture, more than half of the cells
from P4 were CD31+/CD90+, consistent with an endothelial identity. Importantly,
these cells were able to produce new mesenchymal (CDH5−/CD44high) and haemato-
poietic (CD43+) cells, confirming their differentiation potential. In contrast, cells sorted
and re-plated from P1 gate displayed morphology and markers (CD44+/Vimentin+)
consistent with a mesenchymal identity. These mesenchymal cells showed no ability to
differentiate into endothelial cells (i.e. all cells were CDH5−). Furthermore, cell from
the P2 gate (CDH5−/CD44−/CD43+), predicted to label the erythroid population, and
P5 (CDH5+/CD44−/CD43+) exclusively generated erythroid colonies in a CFU assay
(Fig. 3c). In contrast, cells in P3 (CDH5−/CD44+/CD43+) and P6 (CDH5+/CD44+/
CD43+), predicted to label multipotent HPCs, were able to generate an array of
Fig. 3 Sorting and functional validation of distinct populations. a Immunofluorescence staining showing
expression of CDH5, CD44, and CD43 on haematopoietic clusters of cells at EHT D5. Scale bar is 50 μm. b
Flow cytometry analysis showing the sorting strategy for six populations (P1–P6). Results are representative
of at least 3 independent experiments, using 2 distinct hPSC lines. c CFU assay showing the differentiation
potential of cells isolated from P1 to P6. The ability to produce multilineage CFU-GEMM colonies is
compared to the unsorted population. Data are mean ± SEM of 4 independent experiments, with statistical
significance compared to control as *P < 0.5, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by one-way ANOVA.
Degrees of freedom DFn = 6, DFd = 21, value F = 15.21
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colonies (Fig. 3c) including multilineage CFU-GEMM colonies at a higher rate when
compared to unsorted cells.
In addition, we monitored the expression of CD34, CD43, CD44, and CDH5 by flow
cytometry, from EHT D0 to EHT D3 (Additional file 1: Fig. S5). Our time course ex-
periment showed that the described P1–P6 populations are generated over time start-
ing from a population of CD34+/CD43−/CD44+low cells. Importantly, this initial
population of cells at EHT D0 was devoid of any haematopoietic potential.
Although both CDH5+ (P6) and CDH5− (P3) cells displayed multilineage differenti-
ation potential (as shown by CFU assays), immunofluorescence staining showed that
the haematopoietic clusters contained CDH5+ but not CDH5− cells (Fig. 3a). CDH5−
HPCs could only be detected when both the attached and floating fractions of cells
were analysed by flow cytometry, indicating that they were floating in the culture
medium and were most likely derived from CDH5+ HPCs. Thus, variable expression of
CDH5 in HPCs might indicate different stages of their differentiation toward the haem-
atopoietic lineage, with CDH5+ cells representing earlier progenitors and CDH5−
HPCs being more mature progenitors that have detached from the endothelium. This
is in agreement with previous studies showing that HSCs emerging in the AGM express
CDH5, which is then downregulated upon HSC maturation [28].
In summary, these results validate the proposed cell identities and confirm their dif-
ferentiation trajectories, demonstrating that endothelial cells are able to undergo EHT
and endothelial-to-mesenchymal transition (EndoMT) [32–36] to generate haematopoi-
etic and mesenchymal populations, respectively. Additionally, we identified a sorting
strategy to enrich for HPCs generated in vitro and confirmed their multilineage haem-
atopoietic potential using differentiation assays.
Cell cycle progression is required for specification of HPCs
During the course of the experiments described above, we observed that clusters of
HPCs contain cells with a distinct nuclear morphology compared to the surrounding
endothelial and mesenchymal cells. Indeed, a majority of these cells displayed nuclear
condensation typical of mitotic or dividing cells (Fig. 3a) thereby suggesting that HPCs
represent a highly proliferative population. To confirm this observation, we used our
scRNA-seq data to infer the cell cycle state of the HPC, endothelial, mesenchymal, and
early erythroid populations (Fig. 4a) [26]. While endothelial cells were enriched in G1,
mesenchymal cells and HPCs displayed a more active cell cycle. In contrast, erythroid
progenitors appeared to be extremely proliferative with only 2.5% of the cells in G1
(Fig. 4a). In line with this observation, genes belonging to the Rb and CIP/KIP families
such as RB1, RBL2/p130, and CDKN1C/p57, which inhibit G1 progression and G1/S
transition, were gradually downregulated during the transition of endothelial cells to
HPCs and upon their further differentiation to erythroid cells (Additional file 1: Fig.
S6a). Concomitantly, proliferation markers such as MKI67 and CCNB2 were upregu-
lated. Interestingly, we observed differential expression of cyclin D genes that are neces-
sary for the activation of CDK4/6 and progression through the G1 phase. Endothelial
cells were enriched for cyclin D1 and D2, while HPCs appeared to switch to cyclin D2
and D3. The more committed erythroid cluster preferentially expressed cyclin D3 (Add-
itional file 1: Fig. S6a). This might suggest a divergent requirement for cyclin D genes
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during EHT and would be in agreement with genetic studies in the mouse showing that the
simultaneous absence of the three cyclin Ds leads to severe haematopoietic defects [37].
To experimentally validate these observations, we assessed the cell cycle profile of
CD43+ (haematopoietic) and CD43− (endothelial and mesenchymal) cells at different
time points during EHT using EdU incorporation assay (Fig. 4b). These experiments
confirmed that the emerging CD43+ haematopoietic population was characterised by
an active cell cycle profile, while the majority of CD43− cells were in the G1 phase.
Furthermore, we took advantage of FUCCI-hPSCs [38, 39] to monitor changes in cell
cycle phase during EHT (Additional file 1: Fig. S6c). We observed that emerging HPC
clusters contained cells that mainly expressed the reporter specific for S/G2/M phases
(GEMININ), while endothelial cells were found to be either positive for the late G1 re-
porter (CDT1) or negative for both reporters thus indicating G0/early G1 phase (Add-
itional file 1: Fig. S6c). These findings support the notion that the endothelial
differentiation into HPCs is associated with cell cycle entry.
We next asked whether RUNX1+ haemogenic endothelial cells present at EHT D3
could transit to haematopoietic progenitors if their cell cycle progression was blocked. To
address this question, EHT D3 cells were grown for 48 h in the presence of Nocodazole, a
small molecule commonly used to block cell cycle progression [40, 41]. The efficacy of
Nocodazole treatment was confirmed by EdU incorporation analyses showing an expected
enrichment of cells in G2/M (Fig. 4c). However, a significant fraction of cells remained in
G1. These cells most likely represent a quiescent population of endothelial cells (Fig. 4a)
that never entered cell cycle during the 48 h treatment. Following Nocodazole treatment,
cells were washed to allow cell cycle progression and their haematopoietic potential was
assessed by CFU assays. This showed that cell cycle inhibition effectively blocked the gen-
eration of functional haematopoietic cells (Fig. 4d). Consistently, flow cytometry analyses
showed an enrichment in CDH5+ (endothelial) cells and depletion of the CD43+ (haem-
atopoietic) compartment after Nocodazole treatment (Fig. 4e). Importantly, this effect was
not related to non-specific cytotoxicity, as cells treated with Nocodazole only displayed a
minor increase in cell death (Additional file 1: Fig. S6b).
To confirm that blocking cell cycle does not affect the ability of endothelial cells to
subsequently re-enter cell cycle and proliferate, but it rather influences their cell fate
decision by precluding the haematopoietic fate choice, we performed release experi-
ments. Following 48 h Nocodazole treatment from EHT D3 to EHT D5, cells were
washed/released and further cultured for up to 1 week. Following release from cell
cycle block, endothelial cells were able to re-enter cell cycle and resume proliferation,
expanding as a monolayer, possibly composed of a mix of endothelial and mesenchymal
cells. Importantly, immunofluorescence staining confirmed the progressive reduction in
the number of RUNX1+ cells (Fig. 5a). The rare RUNX1+ cells detectable after treat-
ment did not form distinct clusters; displayed an elongated endothelial morphology, as
assessed by immunofluorescence and light microscopy; and were unable to acquire col-
ony forming potential (Fig. 5b). In line with these results, there were no visible HPC
clusters even after one additional week of culture.
Taken together, these experiments confirmed that blocking cell cycle prevents transi-
tion of haemogenic endothelial cells into haematopoietic progenitors (Fig. 5c). Further-
more, when cell cycle is blocked, haemogenic endothelial cells progressively lose the
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Fig. 4 (See legend on next page.)
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expression of RUNX1 and adopt a non-haemogenic endothelial identity or possibly as-
sume a mesenchymal fate.
Inhibition of specific cyclin-dependent kinase (CDK) proteins impairs EHT
To further explore the connection between cell cycle regulation and haematopoi-
etic differentiation, we focused on CDK proteins and their role during EHT.
CDK proteins are key regulators of cell cycle progression and are involved in a
variety of non-canonical functions such as transcriptional activation, DNA dam-
age repair, metabolism, differentiation, and cell fate decision in multiple systems
[39, 42–45]. To this end, we used three well-characterised inhibitors which bind
to CDK proteins and block their phosphorylation activity (PD0332991 for CDK4
and CDK6, RO3306 for CDK1, and Roscovitine for CDK2 and to a minor extent
CDK1) [46–53].
In short, EHT D3 cells were grown in the presence of each inhibitor for 48 h and
were washed and collected at EHT D5 for further analyses. Specifically, we assessed the
cell cycle profile of unenriched populations by EdU staining and the colony forming
capacity of sorted HPCs (Fig. 6). Consistent with the known functional redundancy be-
tween CDKs, the treatments were not able to completely block cell cycle but instead in-
duced enrichment in specific phases. Thus, this approach was fundamentally different
compared to the use of Nocodazole, as it allowed us to examine the role of distinct cell
cycle regulators rather than cell cycle progression. More precisely, inhibition of CDK4/
6 (CDK4/6i) increased the number of cells in G1, Roscovitine (CDK2/1i) did not sig-
nificantly change cell cycle profile, and inhibition of CDK1 (CDK1i) caused an increase
in the number of cells in G2/M (Fig. 6a).
Further analysis revealed that CDK4/6i treatment resulted in a reduction in the num-
ber of CD43+ cells and a modest effect on the frequency of HPCs (Fig. 6b). However,
the differentiation potential of both CDH5+ and CDH5− HPCs was disrupted since
their capacity to form blood colonies was significantly reduced (Fig. 6c). Roscovitine
was not associated with major modifications in the frequency of populations generated
during EHT. Finally, CDK1i significantly decreased the number of HPCs and to a
minor extent the number of erythroid CD43+ cells (Fig. 6b). The smaller fraction of
(See figure on previous page.)
Fig. 4 Cell cycle progression is necessary for EHT. a (Left panel) tSNE plot of the merged data from EHT D3
and EHT D5. Cells were coloured based on the cell cycle phase inferred from scRNA-seq data. (Middle
panel) Cell cycle phase along differentiation trajectory, from endothelial cells (right) to haematopoietic and
mesenchymal branches (left). (Right panel) Pie charts showing the percentage of cells in G1, G2/M, and S
phase in each of the clusters. b EdU staining and flow cytometry were used to monitor the cell cycle
profile of CD43− and CD43+ cells during differentiation. Results are representative of 3 independent
experiments. c–e At EHT D3, media were supplemented either with 0.1% DMSO (CTRL) or with 0.1 μg/ml
Nocodazole (Noc). After 48 h, at EHT D5, cells were either c processed for EdU staining and flow cytometry
to monitor their cell cycle profile, d washed to remove Nocodazole and further cultured in a CFU assay to
reveal their differentiation potential, or e stained for flow cytometry to monitor the distinct populations
previously identified (P1, mesenchymal cells; P4, endothelial cells; P2 and P5, erythroid progenitors; P3 and
P6, HPCs). Results are representative of 3 independent experiments. Data in d and bar plot in e are mean ±
SEM of 3 independent experiments, with statistical significance compared to control as *P < 0.5, **P < 0.01,
***P < 0.001, and ****P < 0.0001 by two-tailed unpaired t test, and representative of 2 distinct hPSC lines.
Degrees of freedom = 4; t values for the distinct colonies in d are BFU-E = 39.62, CFU-E = 15.74, CFU-GM =
6.871, CFU-G = 4.271, CFU-M = 4.867, and CFU-GEMM= 5.196; t value in e = 15.05
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HPCs produced displayed a strong impairment in their differentiation potential as
shown by CFU assays (Fig. 6c). Similarly, the inducible knockdown of CDK1 depleted
the colony forming potential of the EHT culture, thus confirming our results using a
genetic approach (Additional file 1: Fig. S7).
Taken together, these experiments suggest that specific CDKs are necessary not
only for EHT to occur but also for HPCs to establish their full differentiation po-
tential. Importantly, the inhibition of distinct cell cycle regulators, as opposed to
cell cycle block, alters, rather than inhibit, the EHT process leading to HPC
specification.
Fig. 5 Endothelial cells lose haemogenic potential upon cell cycle block. a Immunofluorescence staining
showing the expression of CDH5 and RUNX1 over time. At EHT D3, media were supplemented either with
0.1% DMSO (CTRL) or with 0.1 μg/ml Nocodazole (Noc). After 48 h, at EHT D5, cells were washed and media
refreshed every other day. After cell cycle block is released, cells reprise proliferation, but RUNX1 expression
is gradually lost, with positive cells representing very rare events at EHT D12. Haematopoietic clusters are
outlined in CTRL and consist of RUNX1+ cells that are mainly round shaped and grouped in clusters. These
clusters can also be recognised in the CDH5-stained panel (green), in which they display a typical round
morphology, as opposed to the surrounding elongated endothelial cells. Finally, these clusters can also be
recognised in the DAPI (grey) panel, in which they are characterised by the typical dense nuclear
morphology and brighter appearance compared to endothelial cells. In Nocodazole-treated cultures, all
these features are not present: the few RUNX1+ cells are more scattered and not grouped in clusters; they
mark elongated endothelial cells rather than round cells; these elongated cells are CDH5 positive (green
panel) and thus clearly endothelial; finally, their nuclei do not appear to be denser or brighter than the
surrounding cells, as was the case in haematopoietic clusters found in control. Scale bar is 50 μm. b Forty-
eight hours after Nocodazole release, at EHT D7, cells were collected and cultured in a CFU assay to assess
their differentiation potential. Data are mean ± SEM of 3 independent experiments, with statistical
significance compared to control as *P < 0.5, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by two-tailed
unpaired t test. Degrees of freedom= 4; t values for the distinct colonies are BFU-E = 5.803, CFU-E = 4.02,
CFU-GM = 6.2, CFU-G = 3.625, CFU-M = 7.407, and CFU-GEMM= 5.547. c Diagram summarising the role of
cell cycle progression during EHT
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Inhibition of CDK regulators disrupts EHT
In order to further understand the effect of CDK inhibitors on the EHT process and
the differentiation capacity of HPCs, we performed scRNA-seq analyses on EHT D5
cells grown in the presence of each CDK inhibitor for 48 h. Following quality control,
we analysed 1742 cells treated with CDK4/6i, 2140 with CDK2/1i, and 1741 with
Fig. 6 Functional effect of CDK inhibitors during EHT. a Schematic showing inhibitors used in the experiments
(left panel) and their effect on cell cycle progression (right panel). Samples were treated for 48 h between EHT
D3 and EHT D5 with either 0.1% DMSO (CTRL), 1 μM PD0332991 (CDK4/6i), 10 μM RO3306 (CDK1i), or 4 μM
Roscovitine (CDK2/1i). At EHT D5, cells were either a processed for EdU staining and flow cytometry to monitor
cell cycle profile or b stained for flow cytometry to monitor the frequency of distinct cell populations
generated (P1, mesenchymal cells; P4, endothelial cells; P2 and P5, erythroid progenitors; P3 and P6, HPCs).
Results are representative of 3 independent experiments. c At EHT D5, cells were washed to remove the
inhibitors and two populations of HPCs (corresponding to P3 and P6 in b) were FACS-sorted and further
cultured in a CFU assay to reveal their differentiation potential. Data are mean ± SEM of 3 independent
experiments, with statistical significance compared to control as *P < 0.5, **P < 0.01, ***P < 0.001, and ****P <
0.0001 by one-way ANOVA. Degrees of freedom in b for CDH5− HPCs are DFn = 1.103, DFd = 2.205, F value
11.19, and for CDH5+ HPCs are DFn = 1.046, DFd = 2.092, F value 204.2. Degrees of freedom in c are DFn = 2,
DFd = 6; F values for the distinct colonies in CDH5− HPCs are BFU-E = 2.483, CFU-E = 2.771, CFU-GM= 12.15,
CFU-G = 3.261, CFU-M= 0.8633, and CFU-GEMM= 17.43; F values for the distinct colonies in CDH5+ HPCs are
BFU-E = 12.51, CFU-E = 6.757, CFU-GM= 67.36, CFU-G = 21.71, CFU-M = 19.26, and CFU-GEMM= 30.63
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CDK1i. As expected, in each of the samples, we identified HPC, endothelial, mesenchy-
mal, and erythroid populations (Fig. 7a).
Comparative analysis showed increase in the percentage of endothelial cells upon inhibition
of CDK4/6, associated with a decrease in the erythroid compartment. Endothelial cells are
mostly non-cycling cells (Fig. 4a, b, Additional file 1: Fig. S6a, c), and in control conditions,
their numbers decrease during EHT concomitantly with production of haematopoietic cells
(Fig. 2b). Thus, our data suggest that the increase in endothelial cells following CDK4/6 inhib-
ition, compared to control, is not associated with proliferation but rather with their decreased
transition to the haematopoietic fate, i.e. decreased EHT (Fig. 7b). The percentage of HPCs in
the presence of the inhibitor was comparable to control, confirming our flow cytometry data
(Fig. 6b) However, these HPCs displayed impaired differentiation potential (Fig. 6c). This
could explain the reduction in the erythroid compartment, and why the frequency of HPCs
remained comparable to control despite reduced EHT.
Cells grown in the presence of the CDK1i also displayed increase in the percentage of
endothelial cells and reduction in the erythroid cluster, suggesting a reduced progres-
sion through EHT. However, the number of HPCs was strongly reduced when
Fig. 7 Effect of CDK inhibitors evaluated by single-cell transcriptomics. Samples were treated with different
cell cycle inhibitors, namely PD0332991 (CDK4/6i), Roscovitine (CDK2/1i), and R03306 (CDK1i), or with DMSO
(CTRL). At EHT D5, cells were collected and processed for scRNA-seq. Data from the four samples was
merged and clustered. a tSNE plots showing previously identified cell populations, on the merged samples
(top row) and for each treatment separately (bottom row). b Pie charts showing the percentage and
absolute number of cells for each condition
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compared to control, again in agreement with our previous flow cytometry analyses
(Fig. 6b). This indicates a key role for CDK1 activity in the HPC population.
Next, we inferred the cell cycle state by transcriptome analysis of cells in each of the
clusters across all treatments. Inhibition of CDK4/6 caused an expected enrichment in
G1 of all four populations (Fig. 8a). On the other hand, the inhibition of CDK1 was as-
sociated with the expected enrichment in G2/M in endothelial and mesenchymal clus-
ters (Fig. 8a). Endothelial cells blocked in this phase of the cell cycle most probably
represent those that were undergoing either EHT or EndoMT at the start of the treat-
ment. Indeed, while the majority of endothelial cells are in G1, those that are transi-
tioning to haematopoietic and mesenchymal fates are associated with re-entry into the
cell cycle and display downregulation of cell cycle inhibitors concomitant with
Fig. 8 Cell cycle regulation controls EHT. a Cell cycle marker genes identified in the scRNA-seq dataset were
used to determine the cell cycle profile of individual clusters upon inhibition of distinct CDKs. b Proposed
model for the role of cell cycle during EHT. Endothelial cells need to re-enter the cell cycle in order to progress
through EHT and generate functional HPCs. Additionally, endothelial cells lose their haemogenic potential if cell
cycle entry and progression is prevented upon transient cell cycle block. The process is regulated by CDKs,
which are necessary for EHT and for the acquisition of HPC differentiation potential
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upregulation of proliferation markers (Fig. 4a, b, Additional file 1: Fig. S3). Despite the
presence of the CDK1 inhibitor, few HPCs were found in S/G2/M, indicating that the
treatment either caused HPCs to further differentiate to the erythroid compartment or
it affected their survival. Either options (i.e. differentiation to erythroid progenitors or
cell death of HPCs upon CDK1 inhibition) could account for the decrease in the HPC
cluster compared to pre-treatment levels and for the fact that the remaining HPCs were
mostly in G1 phase, i.e. they were not cycling at the time of the treatment and were
not affected by the inhibition of CDK1 which gets activated in G2/M. Importantly, the
few remaining progenitors, enriched in G1, also displayed a depleted differentiation po-
tential, similarly to HPCs enriched in G1 by the CDK4/6i treatment (Fig. 6c). This sug-
gests that the timely activation of these cell cycle regulators is required for the
acquisition of haematopoietic differentiation potential.
Overall, along with further confirming its requirement for EHT, these results show
that cell cycle regulation controls HPC differentiation. Additionally, the two regulators
possibly play distinct roles in HPCs. CDK4/6 might be necessary for the acquisition of
differentiation potential, as its inhibition preserved the HPC population although nega-
tively affecting its ability to differentiate. CDK1 might be more important for maintain-
ing the HPC population, as the population was eroded when CDK1 was inhibited and
only non-cycling cells were able to preserve the HPC state.
Of note, inhibition of either CDK4/6 or CDK1 resulted in modest but broad transcrip-
tional changes across all cell populations compared to control. We mainly observed
downregulation of genes for ribosomal subunits and enrichment in GO terms involved in
mitochondrial functioning (Additional file 1: Fig. S8, Additional file 2: Tables S1 – S8).
Furthermore, HPCs showed upregulation of genes such as ALAS2 or haemoglobin genes,
suggesting their priming or precocious differentiation toward the erythroid lineage. Im-
portantly, the inhibition of CDK1 was able to affect the transcriptional signature of the
HPC population despite not affecting its cell cycle profile, confirming that this regulator
may play a role during EHT beyond cell cycle regulation. Unlike CDK4/6 and CDK1, the
CDK2/1 inhibitor did not cause major transcriptional changes compared to control, con-
sistent with the fact that this treatment did not affect the EHT process.
To conclude, our single-cell analyses indicate that the inhibition of CDK4/6 and
CDK1 was able to cause transcriptional changes that were not strictly related to cell
cycle progression. Despite the modest extent of these changes, our findings suggest that
these CDKs can participate in a complex crosstalk between cell cycle regulation and
the transcriptional programmes that drive EHT.
In vitro EHT culture recapitulates populations found in the human AGM in vivo
In order to assess the relevance of our findings for human foetal blood development,
we compared the cells generated in our study with a publicly available dataset obtained
from human AGM [54]. Having annotated this data according to the Authors’ original
cell annotations, we then mapped this dataset onto our data. This allowed us to obtain
predictions of the cell identities in our data using the annotations from the in vivo gen-
erated dataset (Additional file 1: Fig. S10a). This approach confirmed that endothelial,
mesenchymal, and haematopoietic cells identified in our study displayed similarity with
corresponding populations described in vivo.
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Furthermore, endothelial cells generated in our system expressed top marker genes
of both haemogenic and arterial endothelium from AGM (Additional file 1: Fig. S10b).
Based on the level of expression of marker genes, in vitro generated endothelial cells
displayed higher similarity to late haemogenic endothelial cells (late HECs), which give
rise to true HSPCs in the AGM [54], rather than early haemogenic endothelial cells
(early HECs). Interestingly, in vitro derived HPCs displayed similarities to end-stage
HSPCs from AGM, albeit maintaining expression of genes expressed in immature
HSPCs such as active cell cycle genes (Additional file 1: Fig. S10b).
Overall, our comparative analysis showed that in vitro generated endothelial and
haematopoietic cells share many similarities to populations found in the human AGM
and thus make a valuable model system for studying EHT.
Discussion
In this study, we have uncovered a link between cell cycle regulation and endothelial-
to-haematopoietic transition (Fig. 8b). By combining a hPSC differentiation system with
single-cell transcriptomics, we gained insights into the mechanisms driving early hu-
man haematopoietic development.
Our data suggest that the function of cell cycle regulators goes beyond their canon-
ical role in proliferation (Additional file 1: Fig. S9). Thus, CDK4/6 appears to be neces-
sary for both specification of HPCs (i.e. EHT) and their further differentiation. In
agreement with our results, genetic studies in the mouse have shown that the cyclin D-
CDK4/6 complex is indeed required for haematopoietic development [37, 55]. CDK1
also appears to be necessary for EHT and for balanced HPC differentiation and sur-
vival. Of note, CDKs are known to be involved in a variety of non-canonical functions
such as transcriptional control and cell fate decision [39, 42–45, 56]. Accordingly, our
results showed that the activation of CDK4/6 and CDK1 is required during EHT. Their
inhibition was able to affect the transcriptional signature of the distinct populations
generated in culture as well as the differentiation capacity of nascent HPCs, further
suggesting that the role of these regulators during EHT is not strictly related to cell
cycle progression.
Based on these results, we propose a tight link between cell cycle regulation and EHT
(Fig. 8b). Our model suggests that haemogenic endothelial cells are a population of qui-
escent or slow proliferating cells. Their transition to the haematopoietic fate is associ-
ated with cell cycle re-entry and the acquisition of an active cell cycle profile. This
ultimately results in the specification of multipotent HPCs, a transitory population of
cells which in the current culture conditions quickly commit to highly proliferative
erythroid progenitors. We have shown that cell cycle progression is necessary for EHT
and that upon blocking cell cycle, haemogenic endothelial cells are unable to transition
to the haematopoietic fate. As a result, they downregulate RUNX1, lose haemogenic
potential, and instead adopt a non-haemogenic endothelial cell identity, even when the
cell cycle block is removed (Fig. 5c, Additional file 1: Fig. S9a). This would suggest that
EHT can occur within a narrow time window during which cell cycle entry and pro-
gression are necessary for the completion of the haemogenic programme. This is pos-
sibly modulated by the timely activation of specific cell cycle regulators.
Recent studies in the mouse have demonstrated that the generation of early haemato-
poietic progenitors in the AGM is associated with a dynamic cell cycle regulation [57].
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Our analysis here goes beyond these initial findings and shows that the endothelial cells
express key cell cycle inhibitors of the Rb and CIP/KIP families, such as RB1, p21, and
p57 (Additional file 1: Fig. S3a). The downregulation of these inhibitors and concomi-
tant expression of key haematopoietic markers in a subset of endothelial cells mark
their re-entry into the cell cycle and the onset of haematopoietic specification. Import-
antly, blocking cell cycle progression effectively prevents this transition, suggesting that
cell cycle could be necessary to orchestrate the expression of key lineage regulators and
thus differentiation mechanisms.
Interestingly, our group has previously shown that hPSCs acquire responsiveness to
distinct differentiation signals during specific phases of the cell cycle, through a post-
translational modulation of SMAD2/3 transcriptional activity controlled by cyclin D-
CDK4/6 [39]. We hypothesise that a similar regulation could occur during EHT and
that CDKs could be required for the acquisition of functional haematopoietic identity.
Accordingly, it was previously reported that CDK6 can bind to RUNX1 and interfere
with its transcriptional activity [58]. RUNX1 is an essential regulator of EHT, which
synergises with other key factors such as TAL1 and GATA2, and is necessary for the
induction of the haematopoietic transcriptional programme. Thus, it is possible that an
important role for the cell cycle machinery is to modulate the timely activation of the
haematopoietic transcriptional network. Importantly, our results show that when this
modulation is impeded by preventing cell cycle progression and disrupting the activa-
tion of the cell cycle machinery, endothelial cells permanently lose their haemogenic
identity. Our data also imply that EndoMT and EHT represent two alternative cell fate
choices undertaken by endothelial cells during foetal haematopoietic development. The
mesenchymal population does not appear to be affected by the perturbations in the cell
cycle used in this study. However, commitment toward mesenchymal cells appears to
take place at an earlier stage, at EHT D0 or earlier, and to be similarly associated with
the expression of cell cycle related genes (Additional file 1: Fig. S3b). This would sug-
gest that despite EndoMT and EHT taking place at slightly different time windows,
endothelial cells similarly need to enter and progress through cell cycle in order to dif-
ferentiate toward both haematopoietic and mesenchymal fates. Further investigations
would allow to explore this possibility and to assess whether blocking cell cycle at an
earlier time point might be able to prevent EndoMT and maximise the number of cells
available for EHT once this block is lifted.
In conclusion, our study has demonstrated a complex interplay between the mo-
lecular machineries that control cell cycle progression and EHT. This is achieved
through the activation of specific cell cycle regulators, which define the transcrip-
tional landscape and control the differentiation potential of populations generated
during EHT. Further understanding the mechanisms involved in the specification
of HSPCs will help to design more effective culture conditions for their ex vivo ex-




Cell lines used in this study were previously authenticated.
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The hIPSC lines A1AT-RR [59] and FSPS13B were maintained as previously de-
scribed [60] on plates coated with 10 μg/ml Vitronectin (STEMCELL Technologies)
and cultured in E6 media supplemented with 2 ng/ml TGFβ (R&D) and 25 ng/ml FGF2
(Dr. Marko Hyvönen, Department of Biochemistry, University of Cambridge). Cells
were maintained at 37 °C and 5% CO2, and passaged every 5–6 days by dissociation
with 0.5 mM EDTA (ThermoFisher Scientific). For coating plates, 10 μg/ml Vitronectin
in PBS (ThermoFisher Scientific) was applied for at least 1 h at room temperature.
Haematopoietic differentiation
Differentiation was performed at 5% O2 by adapting a protocol previously described
[23]. Briefly, a serum-free differentiation (SFD) medium was used, consisting of 75%
Iscove’s modified Dulbecco’s medium (ThermoFisher Scientific) and 25% Ham’s F12
medium (ThermoFisher Scientific) supplemented with 1% N2 (ThermoFisher Scien-
tific), 0.5% B27 (ThermoFisher Scientific), 0.05% BSA (Sigma-Aldrich), 1 mM ascorbic
acid (2-phospho-L-ascorbic acid trisodium salt, Sigma-Aldrich), 4.5 × 10−4 monothiogly-
cerol (Sigma-Aldrich), 2 mM L-glutamine (ThermoFisher Scientific), 150 μg/ml trans-
ferrin (Sigma-Aldrich), and 10 ng/ml penicillin/streptomycin (ThermoFisher Scientific).
Undifferentiated cells were dissociated using 0.5 mM EDTA, and small aggregates were
resuspended in SFD medium supplemented with 10 ng/ml BMP4 (R&D) and cultured
as embryoid bodies (EBs) on non-treated plates (Starlab). After 24 h, an equivalent vol-
ume of SFD was added directly on top to not perturb the small EBs, supplemented with
final concentrations of 10 ng/ml BMP4 and 5 ng/ml FGF2. At day 2, developing EBs
were collected and washed. For this, they were centrifuged 3 min at 100g; gently resus-
pended in SFD supplemented with 10 ng/ml BMP4, 5 ng/ml FGF2, and 3 μM
CHIR99021 (Tocris); and seeded back on the plate. After 24 h, EBs were again collected
and washed, this time by centrifuging at 300g for 3 min, and resuspended in StemPro-
34 SFM (ThermoFisher Scientific) supplemented with 1 mM ascorbic acid, 4.5 × 10−4
monothioglycerol, 2 mM L-glutamine, 150 μg/ml transferrin, 10 ng/ml penicillin/
streptomycin (from now on referred to as complete SP34) containing 5 ng/ml FGF2,
15 ng/ml VEGF (Peprotech), 10 ng/ml IL-6 (R&D), and 5 ng/ml IL-11 (R&D), and cul-
tured for 48 h. At day 5, EBs were again collected, washed, and resuspended in
complete SP34 with 5 ng/ml FGF2, 15 ng/ml VEGF, 10 ng/ml IL-6, 5 ng/ml IL-11, 50
ng/ml SCF (R&D), 5 ng/ml IGF-1 (R&D), and 2 U/ml EPO (R&D) and cultured until
day 8. At this stage, EBs were collected and prepared for sorting. For this, they were in-
cubated for 20 min at 37 °C with collagenase solution, composed of Advanced DMEM/
F12 (ThermoFisher Scientific), 20% KSR (ThermoFisher Scientific), 1% L-glutamine,
and 1mg/ml collagenase IV (ThermoFisher Scientific), followed by 3 min incubation
with TrypLE (ThermoFisher Scientific). Single cells were then stained for flow cytome-
try, and the CD34+/CD43− fraction was sorted and used for the second stage of differ-
entiation. For this, the population was resuspended at a density of 106 cells/ml in
complete SP34 with 10 ng/ml BMP4, 5 ng/ml FGF2, 5 ng/ml VEGF, 10 ng/ml IL-6, 5
ng/ml IL-11, 100 ng/ml SCF, 25 ng/ml IGF-1, 30 ng/ml TPO (Peprotech), 30 ng/ml IL-3
(Peprotech), 10 ng/ml Flt3-L (R&D), 20 ng/ml SHH (R&D), 10 ng/ml angiotensin II
(Sigma-Aldritch), and 100 μM losartan potassium (R&D). Cells were transferred to a
non-treated round-bottom 96-well plate (Corning), 200 μl/well (corresponding to
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2 × 105 cells/well); centrifuged 3 min at 300g; and incubated overnight to allow the
cells to re-aggregate. On the following day, marking EHT D1, the small aggregates
were plated on Matrigel (Corning). For this, they were gently transferred to thin-
layer Matrigel-coated wells, with a density of 2 × 105 cells/well in a 24-well plate,
and cultured for additional 2–4 days using the same media, replaced every 2 days.
For coating plates, Matrigel was diluted into cold medium with a concentration of
35 μg/cm2 of surface to be coated, and applied overnight at 37 °C. For treatments
with cell cycle inhibitors, 0.1 μg/ml Nocodazole (Sigma-Aldrich), 1 μM PD0332991
(Tocris), 4 μM Roscovitine (Sigma-Aldrich), 10 μM RO3306 (Sigma-Aldrich), or
0.1% DMSO were added at EHT D3 for 48 h.
Isolation of CD34+ peripheral blood mononuclear cells
Under sterile conditions, peripheral blood was diluted with room temperature PBS sup-
plemented with 1M trisodium citrate and 20% human serum albumin. Two volumes of
blood dilution were transferred in 50-ml tubes on a layer of 1 volume of Ficoll-Paque
(Sigma-Aldrich). After centrifugation for 15 min at 800g, the resulting layer of mono-
nuclear cells was carefully removed, transferred to a new tube, further diluted using the
same buffer, and centrifuged for 6 min at 600g. The resulting supernatant was removed;
the pellet was resuspended in cold PBS supplemented with 0.5M EDTA and 20% hu-
man serum albumin, and centrifuged again for 6 min at 600g. Cells were then processed
for CD34+ enrichment using labelling with magnetic beads. Briefly, cells were resus-
pended in the same PBS/EDTA/human serum albumin buffer, added with 50 μl/108
cells of FcR blocking reagent (Miltenyi Biotec) and 50 μl/108 cells of CD34 magnetic
beads (Miltenyi Biotec), and incubated for 30 min at 4 °C. After incubation, cells were
washed using the same buffer and processed with AutoMACS Pro Separator to enrich
for CD34+ peripheral blood mononuclear cells.
May-Grünwald-Giemsa staining
Cells were resuspended in culture media and concentrated by cytospin centrifugation
at 700g for 5 min onto SuperFrostPlus slides (ThermoFisher Scientific) using a Shandon
Cytospin 3 cytocentrifuge. Slides were fixed for 3 min in cold methanol and stained
with May-Grünwald-Giemsa (Sigma). Images were captured using a Leica DM5000b
microscope in conjunction with a × 63 oil-immersion lens and an Olympus DP72
camera.
Table 1 Antibodies used for flow cytometry
Target Supplier Clone
CD34 Biolegend 581
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Flow cytometry
Cells were dissociated into single cells using TrypLE for 3 min at 37 °C, washed with
0.1% BSA-PBS, and either fixed with 1% paraformaldehyde and kept at 4 °C for max-
imum 1week or immediately stained for flow cytometry. For the staining, after a wash
with PBS, cells were blocked with 10% donkey serum (Bio-Rad) for 30 min at room
temperature. Cells were then stained with the relevant conjugated antibodies diluted in
PBS for 1 h at room temperature, protected from light (Table 1). Following two washes
with PBS, cells were analysed using the Cyan ADP flow cytometer or sorted on the BD
Influx cell sorter. Data was analysed using the FlowJo VX software.
Cell viability upon Nocodazole treatment was assessed using the Dead Cell Apoptosis
Kit with Annexin V Alexa Fluor 488 & Propidium Iodide (ThermoFisher Scientific).
Table 2 Primers used for qPCR









CYCLIN B1 CGCCTGAGCCTATTTTGGTTG AGTGACTTCCCGACCCAGTA
CYCLIN D1 GCTGTGCATCTACACCGACA AAATGAACTTCACATCTGTGGCA
CYCLIN D2 GCCACCGACTTTAAGTTTGC CGGTACTGCTGCAGGCTATT
CYCLIN D3 TGTGCTACAGATTATACCTTTGCC GCTTCGATCTGCTCCTGACA
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RNA extraction, cDNA synthesis, and qPCR
Total RNA was extracted using the GenElute Mammalian Total RNA Miniprep Kit
(Sigma-Aldrich) and the On-Column DNase I Digestion set (Sigma-Aldrich) according
to the manufacturer’s instructions. RNA was reverse-transcribed using 250 ng random
primers (Promega), 0.5 mM dNTPs (Promega), 20 U RNAseOUT (Invitrogen), 0.01M
DTT (Invitrogen), and 25 U of SuperScript II (Invitrogen). For the qPCR reaction, the
resulting cDNA was diluted 30-fold. Quantitative PCR mixtures were prepared using
the KAPA SYBR FAST qPCR Master Mix Kit (Kapa Biosystems), 4.2 μl of cDNA, and
200 nM of each of the forward and reverse primers (Table 2). Technical duplicates of
the samples were run on 384-well plates using the QuantStudio 12 K Flex Real-Time
PCR System machine, and results analysed using the delta cycle threshold (ΔCt)
method. Expression values were normalised to the housekeeping gene RPLP0.
CFU assay
The assay was performed using the MethoCult H4435 Enriched medium (STEMCELL
Technologies), following the manufacturer’s instructions. Briefly, cells were added in a
tube with the medium, mixed by vortex, plated on non-treated 35-mm culture dishes
(Corning), and incubated for 14 days at 37 °C, 5% CO2 and 5% O2. Different types of
colony were recognised based on morphology, counted, and, when relevant, collected
for RNA extraction.
Cell cycle profile analysis
Cell cycle profile analysis was performed using the Click-iT EdU Alexa Fluor 488 Flow
Cytometry Assay Kit (ThermoFisher Scientific) according to the manufacturer’s instruc-
tions. Briefly, cultured cells were incubated at 37 °C with 10 μM EdU for 1 h and har-
vested after dissociation with TrypLE. After 3 washes with 0.1% BSA-PBS, cells were
fixed with 1% paraformaldehyde for 15 min at room temperature and washed three
more times with 0.1% BSA-PBS. Cells were then permeabilised for 15 min with
saponin-based permeabilisation/wash buffer and incubated with the Click-iT reaction
cocktail for 30 min protected from light. Cells were washed once with saponin-based
permeabilisation/wash buffer, stained for DNA content using DAPI (ThermoFisher Sci-
entific), and analysed on the Cyan ADP flow cytometer and FlowJo VX software.
Immunofluorescence staining
Cells were fixed with 4% paraformaldehyde and kept at 4 °C for maximum 1 week or
immediately stained for immunohistochemistry. Cells were blocked/permeabilised with
1% Donkey serum in PBS + 0.3% Triton X-100 for 1 h, and then incubated with the
Table 3 Antibodies used for immunostaining
Target Supplier Catalogue number
RUNX1 Biolegend 659302
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relevant primary antibodies diluted in PBS + 0.03% Triton X-100 at 4 °C over-
night (Table 3). Cells were then washed three times with PBS and incubated with sec-
ondary antibodies diluted in PBS + 0.03% Triton X-100 at 4 °C for 1 h.
Inducible knockdown
Plasmid carrying an inducible shRNA was generated as previously described [61].
Briefly, shRNA for the CDK1 gene (shCDK1) was obtained from previous publication
[62] and introduced by cloning of annealed oligonucleotides in the sOPTiKD plasmid
between the BglII and SalI-HF sites (Table 4).
The resulting sOPTiKD_shCDK vector was targeted to the AAVS1 locus in combin-
ation with the pZFN.AAVS1-KKR and pZFN.AAVS1-ELD vectors [61]. Single-cell
hPSCs were nucleofected using the Lonza P3 Primary Cell 4D-Nucleofector X Kit and
the cycle CA-137 on a Lonza 4D-Nucleofector System, in feeder-free conditions.
Monoclonal colonies were selected for 7–10 days with 1 μg/ml puromycin (Sigma). Ex-
pression of the shCDK1 was induced during differentiation by adding 1 μg/ml tetracyc-
line hydrochloride (Sigma-Aldrich) at EHT D2. At EHT D5, the efficiency of
knockdown was determined by qPCR, and haematopoietic potential for total culture
was assessed by CFU assay.
Statistical analysis
Statistical analyses were performed using the GraphPad Prism 7 software. The type of
statistical analysis performed and the number of replicates used in each experiment are
described in the figure legends. For the comparison of two or multiple groups, two-
tailed unpaired t test or one-way ANOVA test was performed, respectively. Significance
in each analysis is represented as *P < 0.5, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Single-cell RNA sequencing
Following dissociation, cells were resuspended at a concentration of 1500 cells/μl in
ice-cold SP34 medium, complete with cytokines as for EHT culture. Libraries were
constructed using Chromium Controller and Chromium Single Cell 3′ Library & Gel
Bead Kit (10x Genomics) according to the manufacturer’s instructions for the recovery
of 2000 cells for each sample. Briefly, the cellular suspension was added to the master
mix containing nuclease-free water, RT Reagent Mix, RT Primer, Additive A, and RT
Enzyme Mix. Master mix with cells was transferred to the wells in row 1 on the Chro-
mium Single Cell A Chip (10x Genomics). Single Cell 3′ Gel Beads were transferred in
row 2, and Partitioning Oil was transferred into row 3. The chip was loaded on Chro-
mium Controller to generate single-cell GEMs. GEM-RT was performed in a C1000
Touch Thermal cycler (Bio-Rad) at the following conditions: 53 °C for 45 min, 85 °C for
5 min, held at 4 °C. Post GEM-RT clean-up was performed with DynaBeads MyOne Si-
lane Beads (ThermoFisher Scientific). cDNA was amplified using C1000 Touch
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Thermal cycler at the following conditions: 98 °C for 3 min; 12 cycles of 90 °C for 15 s,
67 °C for 20 s, and 72 °C for 1 min; 72 °C for 1 min, held at 4 °C. Amplified cDNA was
cleaned with the SPRIselect Reagent Kit (Beckman Coulter), and quality was assessed
using 2100 Bioanalyser (Agilent). Libraries were constructed following the manufac-
turer’s protocol and sequenced in pair-end mode on Hi-Seq4000 platform.
Alignment and quantification of sequencing data
Cell Ranger v2.10 was used in order to de-multiplex raw base call (BCL) files generated
by Illumina sequencers into FASTQ files and to perform the alignment, barcode count-
ing, and UMI counting. Ensembl BioMart version 91 was used to generate the reference
genome.
Quality control of sequencing data
Data was filtered based on the Median Absolute Deviation (MAD) of the distribution
of the number of detected genes. In addition, the percentage of mitochondrial content
was set to less than 20%. Following quality control, 1764 single cells from EHT D0,
3877 from EHT D3, 2152 from EHT D5, 1742 from PD0332991 (CDK4/6i), 2140 from
Roscovitine (CDK2/1i), and 1741 from RO3306 (CDK1i) were used in downstream
analyses.
Seurat alignment strategy
In order to perform a direct comparison of clusters that belonged to the same cell type
across different conditions, we adopted the Seurat alignment workflow [26]. We calcu-
lated highly variable genes (HVGs) for each of the different conditions. HVGs were de-
tected based on their average expression against their dispersion, by means of the
‘FindVariableGenes’ Seurat command with the following parameters: mean.function
equal to ExpMean, dispersion.function equal to LogVMR, x.low.cutoff equal to 0.0125,
x.high.cutoff equal to 3, and y.cutoff equal to 0.5. For the analysis of EHT D3 and EHT
D5 we selected 1289 common HVGs that were expressed in both datasets. For the ana-
lysis of EHT D5, CDK4/6i, CDK2/1i, and CDK1i, we selected 2306 HVGs that were
expressed in at least 2 out of 4 samples. Canonical correlation analysis (CCA) was then
performed in order to identify shared correlation structures across the different condi-
tions using the ‘RunMultiCCA’ command. A total of 30 and 35 CCA components were
selected for the EHT D3-EHT D5 and the EHT D5-CDK4/6i-CDK2/1i-CDK1i analysis,
respectively, by means of the shared correlation strength, using the ‘MetageneBicorPlot’
Seurat command. Aligned CCA space was then generated with the ‘AlignSubspace’
Seurat command. Significant CCA aligned components were then used to create the
3D tSNE space using the ‘RunTSNE’ Seurat command.
Downstream analysis of sequencing data
For the clustering in the 3D tSNE space, we used the ‘FindClusters’ command in
Seurat that performs the Shared Nearest Neighbour (SNN) modularity optimisation
based clustering algorithm in correlation component analysis (CCA) aligned space.
In total, thirteen clusters were identified using SNN modularity optimisation-based
clustering algorithm on the significant CCA aligned components at 0.6 resolution.
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Positive marker genes that were expressed in at least half of the cells within the
thirteen identified clusters were calculated with ‘FindAllMarkers’ Seurat command,
using the Wilcoxon rank sum test with the threshold set to 0.25. We over-
clustered the cells and then calculated for each cluster the average expression level
of the top 20 marker genes. After calculating the correlation across the clusters,
we merged those with a correlation higher than 0.9. By merging the most highly
correlated, we ended up with 4 clusters, and by calculating marker genes, we were
able to assign cell identity to the resulting clusters.
Pseudotime ordering
The set of common HVGs (1289 genes) was used to order cells along a pseudotime tra-
jectory using the Monocle2 R package v1.99.0. Monocle object was created using the
‘importCDS’ command applied to the previous step generated Seurat object. The pseu-
dotime trajectory was generated by means of the ‘reduceDimension’ command using as
additional parameters the ‘DDRTree’ reduction method, number of resulted compo-
nents equal to three, and pseudo-expression equal to one, using the variance-stabilised
matrix of the expression values (norm_method = ‘log’). Finally, we identified genes that
change as a function of pseudotime across each of the three branches by setting the
‘fullModelFormulaStr’ parameter equal to ‘~sm.ns(Pseudotime)’. For the subclustering,
we retrieved only the endothelial cluster Seurat-based defined cells (cluster 1) and per-
formed separate Louvain clustering on the monocle space ending up with four
subclusters.
Cell cycle analysis
In order to infer cell cycle states in our single-cell data, we adopted Satija’s single-cell
scoring strategy [26]. In more details, we assigned to each cell a score based on its ex-
pression of G2/M and S phase markers. These marker sets should be anticorrelated in
their expression levels, and cells not expressing either are likely not cycling or in G1
phase. We assigned scores in the ‘CellCycleScoring’ function, which stores S and G2/M
scores in ‘object@meta.data’, along with the predicted classification of each cell in ei-
ther G2M, S, or G1 phase.
Comparative analysis
The GEO dataset GSE135202 derived from human foetal AGM [53] was located, and
the relevant raw count data from the corresponding single-cell samples GSM3993420:
CS10_body_10x, GSM3993421:CS11_CH_10x, and GSM3993422:CS13_DA_10x were
collected, including their annotation found in Table S3 (Cell annotation and coordi-
nates of early and late populations), related to Figs. 1, 2, 3, and 4 of the main manu-
script. In order to verify that the data were collected properly and the cell type
correctly annotated and matched to the publication, we processed the raw counts using
FindIntegrationAnchors and IntegrateData Seurat (v3.1) commands, as previously de-
scribed [63]. Having confirmed that cells of similar cell type were clustered together
forming well-defined clusters in UMAP space, we used the specific dataset as a refer-
ence and mapped the defined cell types into our data. This was performed by means of
the Referenced Based Integration and Label Transfer Seurat approach [63], using
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FindTransferAnchors and TransferData Seurat (v3.1) commands. We set as unknown
cell type cells that scored less than 30% prediction probability score. Cell types that
were present in GSE135202 but not predicted in our tSNE space were also omitted
from the plot. This allowed us to represent our control samples in tSNE space coloured
based on GSE135202 predictions. Additionally, custom clustering analysis was per-
formed using the Louvain clustering method (FindNeighbors and FindClusters Seurat
commands) at 0.3 resolution. Finally, expression of marker genes defining key popula-
tions in Figs. 1, 2, 3, and 4 of the main manuscript were assessed against the cell clus-
ters defined in our study.
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